Abstract 38P
Background
Immune Checkpoint Inhibitors (ICIs) have substantially improved the prognosis of metastatic melanoma. However, not all patients benefit equally. To optimize patient selection for ICIs and minimize immune-related toxicity in those with a low likelihood of response, it is essential to identify predictive biomarkers. Our study assessed the association between certain patient characteristics and response to ICIs, progression-free survival (PFS), and overall survival (OS).
Methods
In this retrospective, observational study, we included 49 patients with metastatic melanoma treated with Pembrolizumab or with Nivolumab + Ipilimumab. Collected parameters included sex, age, BRAF V600E mutation status, localization of metastases, baseline lactate dehydrogenase (LDH) and neutrophil to lymphocyte ratio (NLR), best overall response (bOR) achieved, development and type of immune related adverse events (irAEs), dates of progression and death. All statistical analyses were performed using Jamovi, version 2.5.4.
Results
Most patients (57.1%) received Nivolumab + Ipilimumab, with an Overall Response Rate (ORR) of 35.7%, while ORR for Pembrolizumab was 28.5%. For the entire cohort, median PFS and OS were 9.1 months and 21 months, respectively. We found a significant association between the response to ICIs and irAEs, with a relative risk (RR) of 2.93 (p= 0.01). Cutaneous irAEs, including vitiligo, occurred in 52.4% of patients and were associated with a higher RR of 3.45 (p = 0.003). There was no association between response to ICIs and LDH, NLR, sex, age or BRAF status. Patients with elevated LDH (>245 U/L) had significantly shorter OS than those with normal LDH, with HR: 3.26 (95% CI: 1.16-9.17), p < 0.05. Similarly, patients with elevated NLR (cut-off values: 3.46 for PFS, 4.13 for OS) had significantly shorter PFS and OS than those with low NLR (p < 0.05), with corresponding hazard ratios of 1.23 (95% CI: 1.03-1.47) for PFS and 1.34 (95% CI: 1.09-1.64) for OS.
Conclusions
The development of irAEs, particularly cutaneous irAEs, may serve as an indicator of response to ICIs in metastatic melanoma patients. Baseline LDH and NLR levels have prognostic significance, but are not predictive of response to ICIs.
Editorial acknowledgement
During the preparation of this work the author(s) used ChatGPT in order to rephrase sentences, make them shorter/ more concise in order to better express the meaning and fit inside the character limit. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
Resources:
Abstract
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
Resources:
Abstract
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
Resources:
Abstract
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session
Resources:
Abstract
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract